NCT05759897 is a Phase 2 clinical trial of HRS-7535 in Type 2 Diabetes, sponsored by Shandong Suncadia Medicine Co., Ltd..

Who is sponsoring NCT05759897?

NCT05759897 is sponsored by Shandong Suncadia Medicine Co., Ltd..

What drugs are being tested in NCT05759897?

Interventions in NCT05759897: HRS-7535, Placebo.

What condition does NCT05759897 study?

NCT05759897 studies Type 2 Diabetes.

Is NCT05759897 still recruiting?

NCT05759897 is currently status unknown. Last updated 8 March 2023.

Last reviewed 2023-03-08 · How we verify

NCT05759897

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus

Status unknown Phase 2 Last updated 8 March 2023

What this trial tests

Phase 2 trial testing HRS-7535 in Type 2 Diabetes in 180 participants. Status unknown.

Timeline

28 February 2023

Primary endpoint
21 December 2023

4 January 2024

Quick facts

Lead sponsor	Shandong Suncadia Medicine Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	180
Start date	28 February 2023
Primary completion	21 December 2023
Estimated completion	4 January 2024

Drugs / interventions tested

HRS-7535
Placebo

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Shandong Suncadia Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with type 2 diabetes mellitus.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach.
Șeremet OC, Pușcașu C, Andrei C, Nițulescu G, et al · · 2025 · cited 1× · PMID 41303737 · DOI 10.3390/medicina61111902
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.
Guo L, Sun Z, Zhang L, Qin G, et al · · 2026 · PMID 42234428 · DOI 10.1001/jamanetworkopen.2026.15622

Verify or expand the search:

Other trials of HRS-7535

Trials testing the same drug.

NCT06671821 — Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects · Phase 2 · completed
NCT06415214 — Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes · Phase 2 · completed
NCT06393348 — Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i. · Phase 2 · completed
NCT05347758 — A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinet · Phase 1 · unknown

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Shandong Suncadia Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07272330 — A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects · Phase 1 · completed
NCT07269756 — A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese · Phase 1 · completed
NCT07229560 — A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants · Phase 1 · completed
NCT07097831 — A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects · Phase 1 · completed
NCT06961643 — Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05759897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Suncadia Medicine Co., Ltd.
Last refreshed: 8 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing